MOTS-c in Bone, Cartilage and Intervertebral Disc Models: Osteoclasts, Osteoblasts and a Retracted Study

RESEARCH · MOTS-C · BONE, CARTILAGE & DISC MODELS

MOTS-c in Bone, Cartilage and Intervertebral Disc Models: Osteoclasts, Osteoblasts and a Retracted Study

PurixLab’s MOTS-C 10mg is a research vial of the 16-amino-acid mitochondrial-derived peptide MOTS-c. Our earlier articles cover a research overview, rodent obesity and diabetes models, exercise and AMPK signalling, circulating levels in humans and lyophilized peptide stability. This article turns to a smaller and less discussed literature: experiments on bone, cartilage and the intervertebral disc. Almost all of it comes from cell culture and rodent models, and one frequently grouped study has since been retracted. These are findings from published research; the vial is supplied for laboratory research use only, and nothing here is treatment guidance or a claim about any PurixLab product.

Starting point: a muscle-targeted metabolic peptide

MOTS-c was described in 2015 as a 16-amino-acid peptide encoded by a short open reading frame within the mitochondrial 12S rRNA. In that work its primary target organ appeared to be skeletal muscle, and its cellular actions inhibited the folate cycle and de novo purine biosynthesis, leading to AMPK activation [1]. AMPK reappears in nearly every skeletal study below. A 2023 review summarised reports that MOTS-c promotes osteoblast proliferation, differentiation and mineralisation and inhibits osteoclast production, while noting that the mechanism by which exercise regulates MOTS-c in bone remains unclear [2]. A 2024 review placed mitochondrial-derived peptides among the effector molecules of mitohormesis, an adaptive mitochondrial stress response that it links with osteoarthritis, intervertebral disc degeneration and osteoporosis [3].

Bone resorption: osteoclasts and osteolysis

The first skeletal study used ovariectomised mice, a standard model of oestrogen-deficiency bone loss. After 12 weeks of MOTS-c treatment, micro-CT showed that bone loss was significantly alleviated. In culture, MOTS-c markedly inhibited RANKL-induced osteoclast differentiation and increased phosphorylated AMPK, but the AMPK inhibitor compound C only partially abrogated the effect on osteoclastogenesis [4], so AMPK may not be the whole explanation.

A second mouse study used calvarial osteolysis induced by ultra-high molecular weight polyethylene (UHMWPE) particles. MOTS-c alleviated bone erosion and inflammation and increased the osteoprotegerin (OPG)/RANKL ratio in osteocytes, which the authors linked to reduced osteoclastogenesis. In primary bone marrow macrophages it reduced particle-triggered STAT1 and NF-κB phosphorylation, and repressing the AMPK-PGC-1α axis or promoting ROS production blocked these anti-inflammatory effects [5].

A third study examined a mouse model of bone cancer pain. Plasma MOTS-c was significantly lower in the bone cancer group than in sham animals, and intraperitoneal MOTS-c attenuated pain behaviour, an effect blocked by compound C. The authors described central actions in the spinal cord, including restored mitochondrial biogenesis and reduced microglial activation, and peripheral protection against local bone destruction through effects on osteoclasts and immune cells. They also reported that chronic administration had little effect on liver, renal, lipid or cardiac function in mice [6].

Bone formation: marrow stromal cells and osteoblasts

On the formation side, a study in rat bone marrow mesenchymal stem cells (BMSCs) reported that MOTS-c stimulated the formation of calcified nodules and upregulated TGF-β/Smad pathway genes, and that TGF-β1 knockdown reversed the pro-osteogenic effect [7]. In the human fetal osteoblast line hFOB1.19, cell viability increased after 1.0 μM MOTS-c for 24 h or 0.5 μM for 48 h, and the peptide increased COL1A1 and COL1A2, the genes for type I collagen, an effect partially reversed by knockdown of TGF-β or SMAD7 [8].

Both papers have “improves osteoporosis” in their titles, yet neither abstract describes an animal model of osteoporosis: the evidence they present is from cultured cells [7,8]. That distinction matters when the bone literature is summarised as showing benefit in osteoporosis.

A retracted fracture-healing paper

A 2019 paper reported that MOTS-c accelerated fracture healing by stimulating osteogenesis of rat BMSCs through FOXF1 and the TGF-β pathway [9]. In 2021 the journal published a retraction notice stating that the article had been withdrawn by the authors due to inaccuracies during the process of organising the images [10]. Its results should not be counted as evidence. The episode is a reminder to check retraction status in PubMed before tallying “positive” studies for any peptide, particularly in small literatures where one paper can shift the impression of consistency.

Cartilage and the intervertebral disc

In chondrocytes exposed to lipopolysaccharide, MOTS-c improved mitochondrial dysfunction, rescued pyroptosis through an Nrf2/TXNIP/NLRP3 axis, promoted the expression of major extracellular matrix components and suppressed matrix metalloproteinases. In a murine osteoarthritis model, imaging and histopathology indicated delayed degeneration of articular cartilage [11].

Disc work has gone a step further into biomaterials. In nucleus pulposus-derived mesenchymal stem cells exposed to tert-butyl hydroperoxide, MOTS-c reduced apoptotic cells by 48%, senescent cells by 52% and ROS by 35% through AMPK/SIRT1 signalling, and SIRT1 inhibition abolished the protection. The authors then conjugated MOTS-c to the self-assembling peptide RADA16-I to make a hydrogel with sustained release over 7 days; in a rat disc degeneration model the hydrogel preserved disc height index (82.4 versus 58.7 in untreated degeneration) [12]. The in vivo result therefore describes a peptide-hydrogel construct, not the free peptide.

Reading this literature critically

  • Model systems. The skeletal data are from cell lines, primary cells and mice or rats [2]. In a PubMed search on 23 October 2026 we found no study measuring bone or joint outcomes in humans given MOTS-c.
  • Mechanism. AMPK is the recurring explanation, but inhibitor experiments gave partial reversal in one study [4], and TGF-β/Smad, Nrf2 and SIRT1 pathways were each invoked in others [7,11,12].
  • Replication. Each finding rests on a single group’s experiments, and one paper in the set was retracted [10].
  • Material form. Free peptide, a hydrogel conjugate and a cancer-pain model with central effects are different experimental questions and cannot simply be pooled [12,6].

What remains open

  • Whether endogenous MOTS-c in bone or cartilage changes with age, unloading or disease in people, and whether circulating levels relate to bone density.
  • Whether the osteoarthritis and disc results reproduce in other injury models and in independent laboratories.
  • How MOTS-c reaches and persists in poorly vascularised tissues such as cartilage and the disc, and what analytical methods would confirm its presence there.

MOTS-C 10mg at PurixLab

MOTS-C 10mg: a labelled lyophilized research vial with 10mg per vial, C$54 per vial (CAD, before tax), supplied for laboratory research only. Batch documentation is available on request. Product page: purixlab.com/product/mots-c-10mg/.

PurixLab ships within Canada only, from stock held in Toronto. Standard shipping is C$15, and shipping is free when the product subtotal is C$200 or more after discounts. Orders outside the GTA ship by Canada Post Xpresspost. Prices are in CAD and taxes are calculated from your shipping address at checkout.

In Toronto and the GTA, our own team delivers orders the same day or the next day. There is no fixed GTA delivery fee: after you place your order, we email you to confirm the delivery time and any delivery charge, and then you pay. There is no storefront or local pickup.

Payment is by Interac e-Transfer (instructions are shown at checkout) or by cryptocurrency through Plisio (Bitcoin, Ethereum, USDT and more): choose Plisio at checkout and you are sent to a secure Plisio payment page after placing the order. Current offers and any pack pricing are shown on the product page and in your cart; offers do not stack.

For laboratory research use only. Not for human or veterinary use, not for consumption, injection or application to skin, and purchasers must be 18 or older. The studies summarised above describe specific materials in published research; they are not claims about any PurixLab product.

View MOTS-C 10mg

Questions or batch documentation requests: [email protected] · Shipping & Delivery · Toronto & GTA delivery · PurixLab FAQ

References

  1. Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-54. PubMed 25738459 · PMC4350682 · doi:10.1016/j.cmet.2015.02.009
  2. Yi X, Hu G, Yang Y, et al. Role of MOTS-c in the regulation of bone metabolism. Front Physiol. 2023;14:1149120. PubMed 37200834 · PMC10185875 · doi:10.3389/fphys.2023.1149120
  3. Da W, Chen Q, Shen B. The current insights of mitochondrial hormesis in the occurrence and treatment of bone and cartilage degeneration. Biol Res. 2024;57(1):37. PubMed 38824571 · PMC11143644 · doi:10.1186/s40659-024-00494-1
  4. Ming W, Lu G, Xin S, et al. Mitochondria related peptide MOTS-c suppresses ovariectomy-induced bone loss via AMPK activation. Biochem Biophys Res Commun. 2016;476(4):412-419. PubMed 27237975 · doi:10.1016/j.bbrc.2016.05.135
  5. Yan Z, Zhu S, Wang H, et al. MOTS-c inhibits Osteolysis in the Mouse Calvaria by affecting osteocyte-osteoclast crosstalk and inhibiting inflammation. Pharmacol Res. 2019;147:104381. PubMed 31369811 · doi:10.1016/j.phrs.2019.104381
  6. Yang L, Li M, Liu Y, et al. MOTS-c is an effective target for treating cancer-induced bone pain through the induction of AMPK-mediated mitochondrial biogenesis. Acta Biochim Biophys Sin (Shanghai). 2024;56(9):1323-1339. PubMed 38716540 · PMC11532206 · doi:10.3724/abbs.2024048
  7. Hu BT, Chen WZ. MOTS-c improves osteoporosis by promoting osteogenic differentiation of bone marrow mesenchymal stem cells via TGF-β/Smad pathway. Eur Rev Med Pharmacol Sci. 2018;22(21):7156-7163. PubMed 30468456 · doi:10.26355/eurrev_201811_16247
  8. Che N, Qiu W, Wang JK, et al. MOTS-c improves osteoporosis by promoting the synthesis of type I collagen in osteoblasts via TGF-β/SMAD signaling pathway. Eur Rev Med Pharmacol Sci. 2019;23(8):3183-3189. PubMed 31081069 · doi:10.26355/eurrev_201904_17676
  9. Weng FB, Zhu LF, Zhou JX, et al. MOTS-c accelerates bone fracture healing by stimulating osteogenesis of bone marrow mesenchymal stem cells via positively regulating FOXF1 to activate the TGF-β pathway. Eur Rev Med Pharmacol Sci. 2019;23(24):10623-10630. PubMed 31858528 · doi:10.26355/eurrev_201912_19759
  10. Weng FB, Zhu LF, Zhou JX, et al. MOTS-c accelerates bone fracture healing by stimulating osteogenesis of bone marrow mesenchymal stem cells via positively regulating FOXF1 to activate the TGF-β pathway. Eur Rev Med Pharmacol Sci. 2021;25(6):2459. PubMed 33829422 · doi:10.26355/eurrev_202103_25396
  11. Li K, Yang T, Chen F, et al. MOTS-c attenuates mitochondrial dysfunction induces pyroptosis and cartilage degradation in osteoarthritis via an Nrf2-Dependent Mechanism. Free Radic Biol Med. 2025;241:717-731. PubMed 41043625 · doi:10.1016/j.freeradbiomed.2025.09.056
  12. Lin Y, Yang RY, Li J, et al. MOTS-c-modified functional self-assembly peptide hydrogels enhance the activity of nucleus pulposus-derived mesenchymal stem cells of intervertebral disc degeneration. Mater Today Bio. 2025;32:101872. PubMed 40510834 · PMC12159495 · doi:10.1016/j.mtbio.2025.101872

Leave a Comment

Your email address will not be published. Required fields are marked *